Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Recommendations for the clinical management of the elderly patient with malignant lymphoma.

Specht L, Aleman B, Eich H, Illidge TM, Kirova Y, Mikhaeel NG, Ricardi U, Yahalom J; International Lymphoma Radiation Oncology Group (ILROG).

Ann Oncol. 2018 Jan 19. doi: 10.1093/annonc/mdy029. [Epub ahead of print] No abstract available.

PMID:
29360921
2.

The anti-PD-1 era - an opportunity to enhance radiotherapy for patients with bladder cancer.

Walshaw RC, Honeychurch J, Illidge TM, Choudhury A.

Nat Rev Urol. 2017 Oct 31. doi: 10.1038/nrurol.2017.172. [Epub ahead of print] Review.

PMID:
29089607
3.

Akt inhibition improves long-term tumour control following radiotherapy by altering the microenvironment.

Searle EJ, Telfer BA, Mukherjee D, Forster DM, Davies BR, Williams KJ, Stratford IJ, Illidge TM.

EMBO Mol Med. 2017 Dec;9(12):1646-1659. doi: 10.15252/emmm.201707767.

4.

A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells.

Cheadle EJ, Lipowska-Bhalla G, Dovedi SJ, Fagnano E, Klein C, Honeychurch J, Illidge TM.

Leukemia. 2017 Oct;31(10):2278. doi: 10.1038/leu.2017.218. Epub 2017 Jul 28.

PMID:
28751765
5.

Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade.

Dovedi SJ, Cheadle EJ, Popple AL, Poon E, Morrow M, Stewart R, Yusko EC, Sanders CM, Vignali M, Emerson RO, Robins HS, Wilkinson RW, Honeychurch J, Illidge TM.

Clin Cancer Res. 2017 Sep 15;23(18):5514-5526. doi: 10.1158/1078-0432.CCR-16-1673. Epub 2017 May 22.

PMID:
28533222
6.

A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells.

Cheadle EJ, Lipowska-Bhalla G, Dovedi SJ, Fagnano E, Klein C, Honeychurch J, Illidge TM.

Leukemia. 2017 Jul;31(7):1611-1621. doi: 10.1038/leu.2016.352. Epub 2017 Nov 28. Erratum in: Leukemia. 2017 Jul 28;:.

7.

Stereotactic ablative radiotherapy and immunotherapy combinations: turning the future into systemic therapy?

Walshaw RC, Honeychurch J, Illidge TM.

Br J Radiol. 2016 Oct;89(1066):20160472. doi: 10.1259/bjr.20160472. Epub 2016 Sep 14. Review.

8.

Antitumor Efficacy of Radiation plus Immunotherapy Depends upon Dendritic Cell Activation of Effector CD8+ T Cells.

Dovedi SJ, Lipowska-Bhalla G, Beers SA, Cheadle EJ, Mu L, Glennie MJ, Illidge TM, Honeychurch J.

Cancer Immunol Res. 2016 Jul;4(7):621-630. doi: 10.1158/2326-6066.CIR-15-0253. Epub 2016 May 30.

9.

Improving therapeutic activity of anti-CD20 antibody therapy through immunomodulation in lymphoid malignancies.

Lipowska-Bhalla G, Fagnano E, Illidge TM, Cheadle EJ.

Leuk Lymphoma. 2016;57(6):1269-80. doi: 10.3109/10428194.2016.1157874. Epub 2016 Apr 6. Review.

PMID:
27050042
10.

Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to anti-tumor efficacy in murine solid tumor models which can be potentiated by combination with fractionated radiotherapy.

Dovedi SJ, Adlard AL, Ota Y, Murata M, Sugaru E, Koga-Yamakawa E, Eguchi K, Hirose Y, Yamamoto S, Umehara H, Honeychurch J, Cheadle EJ, Hughes G, Jewsbury PJ, Wilkinson RW, Stratford IJ, Illidge TM.

Oncotarget. 2016 Mar 29;7(13):17035-46. doi: 10.18632/oncotarget.7928.

11.

Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study.

Illidge TM, McKenzie HS, Mayes S, Bates A, Davies AJ, Pettengell R, Stanton L, Cozens K, Hampson G, Dive C, Zivanovic M, Tipping J, Gallop-Evans E, Radford JA, Johnson PW.

Br J Haematol. 2016 Apr;173(2):274-82. doi: 10.1111/bjh.13954. Epub 2016 Feb 5.

PMID:
26849853
13.

Consensus guidelines for the detection of immunogenic cell death.

Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, Bracci L, Breckpot K, Brough D, Buqué A, Castro MG, Cirone M, Colombo MI, Cremer I, Demaria S, Dini L, Eliopoulos AG, Faggioni A, Formenti SC, Fučíková J, Gabriele L, Gaipl US, Galon J, Garg A, Ghiringhelli F, Giese NA, Guo ZS, Hemminki A, Herrmann M, Hodge JW, Holdenrieder S, Honeychurch J, Hu HM, Huang X, Illidge TM, Kono K, Korbelik M, Krysko DV, Loi S, Lowenstein PR, Lugli E, Ma Y, Madeo F, Manfredi AA, Martins I, Mavilio D, Menger L, Merendino N, Michaud M, Mignot G, Mossman KL, Multhoff G, Oehler R, Palombo F, Panaretakis T, Pol J, Proietti E, Ricci JE, Riganti C, Rovere-Querini P, Rubartelli A, Sistigu A, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Sukkurwala AQ, Tartour E, Thorburn A, Thorne SH, Vandenabeele P, Velotti F, Workenhe ST, Yang H, Zong WX, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Dec 13;3(9):e955691. eCollection 2014 Oct. Review.

14.

Immuno-regulatory antibodies for the treatment of cancer.

Honeychurch J, Cheadle EJ, Dovedi SJ, Illidge TM.

Expert Opin Biol Ther. 2015 Jun;15(6):787-801. doi: 10.1517/14712598.2015.1036737. Epub 2015 Apr 16. Review.

PMID:
25882106
15.

Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade.

Dovedi SJ, Adlard AL, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle EJ, Stratford IJ, Poon E, Morrow M, Stewart R, Jones H, Wilkinson RW, Honeychurch J, Illidge TM.

Cancer Res. 2014 Oct 1;74(19):5458-68. doi: 10.1158/0008-5472.CAN-14-1258.

16.

Challenging CD30-positive lymphomas--current challenges, new insights and future directions: joining a conversation on CD30+ lymphomas.

Gisselbrecht C, Borchmann P, D'Amore F, Illidge TM, Zinzani PL.

Leuk Res. 2014 Sep;38(9):1003. doi: 10.1016/j.leukres.2014.08.013. Epub 2014 Aug 23. No abstract available.

17.

Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome).

Dummer R, Duvic M, Scarisbrick J, Olsen EA, Rozati S, Eggmann N, Goldinger SM, Hutchinson K, Geskin L, Illidge TM, Giuliano E, Elder J, Kim YH.

Ann Oncol. 2014 Sep;25(9):1807-12. doi: 10.1093/annonc/mdu231. Epub 2014 Jun 19.

PMID:
24948692
18.

Emerging opportunities for the combination of molecularly targeted drugs with radiotherapy.

Searle EJ, Illidge TM, Stratford IJ.

Clin Oncol (R Coll Radiol). 2014 May;26(5):266-76. doi: 10.1016/j.clon.2014.02.006. Epub 2014 Mar 4. Review.

PMID:
24602563
19.

A novel systemically administered Toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models.

Adlard AL, Dovedi SJ, Telfer BA, Koga-Yamakawa E, Pollard C, Honeychurch J, Illidge TM, Murata M, Robinson DT, Jewsbury PJ, Wilkinson RW, Stratford IJ.

Int J Cancer. 2014 Aug 15;135(4):820-9. doi: 10.1002/ijc.28711. Epub 2014 Jan 17.

20.

Fractionated ⁹⁰Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF/BNLI criteria.

Illidge TM, Mayes S, Pettengell R, Bates AT, Bayne M, Radford JA, Ryder WD, Le Gouill S, Jardin F, Tipping J, Zivanovic M, Kraeber-Bodere F, Bardies M, Bodet-Milin C, Malek E, Huglo D, Morschhauser F.

J Clin Oncol. 2014 Jan 20;32(3):212-8. doi: 10.1200/JCO.2013.50.3110. Epub 2013 Dec 2.

PMID:
24297953
21.

New opportunities for anti-CD20 monoclonal antibody to give a direct punch to the tumor.

Illidge TM, Cheadle EJ, Honeychurch J.

Leuk Lymphoma. 2014 Jan;55(1):3-4. doi: 10.3109/10428194.2013.797976. Epub 2013 Oct 24. No abstract available.

PMID:
24047477
22.

Synchronous apoptosis in established tumors leads to the induction of adaptive immunity.

Honeychurch J, Dive C, Illidge TM.

Oncoimmunology. 2013 Jun 1;2(6):e24501. Epub 2013 Apr 16.

23.

The induction of immunogenic cell death by type II anti-CD20 monoclonal antibodies has mechanistic differences compared with type I rituximab.

Cheadle EJ, Sidon L, Dovedi SJ, Melis MH, Alduaij W, Illidge TM, Honeychurch J.

Br J Haematol. 2013 Sep;162(6):842-5. doi: 10.1111/bjh.12427. Epub 2013 Jun 18. No abstract available.

PMID:
23772929
24.

Sustained tumour eradication after induced caspase-3 activation and synchronous tumour apoptosis requires an intact host immune response.

Melis MH, Simpson KL, Dovedi SJ, Welman A, MacFarlane M, Dive C, Honeychurch J, Illidge TM.

Cell Death Differ. 2013 May;20(5):765-73. doi: 10.1038/cdd.2013.8. Epub 2013 Feb 15.

25.

Immunogenic potential of irradiated lymphoma cells is enhanced by adjuvant immunotherapy and modulation of local macrophage populations.

Honeychurch J, Melis MH, Dovedi SJ, Mu L, Illidge TM.

Leuk Lymphoma. 2013 Sep;54(9):2008-15. doi: 10.3109/10428194.2013.769219. Epub 2013 Feb 18.

PMID:
23339450
26.

Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma.

Dovedi SJ, Melis MH, Wilkinson RW, Adlard AL, Stratford IJ, Honeychurch J, Illidge TM.

Blood. 2013 Jan 10;121(2):251-9. doi: 10.1182/blood-2012-05-432393. Epub 2012 Oct 18.

27.

Radiotherapy physics research in the UK: challenges and proposed solutions.

Mackay RI, Burnet NG, Green S, Illidge TM, Staffurth JN; NCRI CTRad EXECUTIVE GROUP.

Br J Radiol. 2012 Oct;85(1018):1354-62.

28.

Methodological considerations in the evaluation of radiotherapy technologies.

Burnet NG, Billingham LJ, Chan CS, Hall E, Macdougall J, Mackay RI, Maughan TS, Nutting CM, Staffurth JN, Illidge TM; National Cancer Research Institute Clinical and Translational Radiotherapy Research Working Group Executive Group.

Clin Oncol (R Coll Radiol). 2012 Dec;24(10):707-9. doi: 10.1016/j.clon.2012.06.003. Epub 2012 Jul 12. No abstract available.

PMID:
22795231
29.

Obinutuzumab (GA101)--a different anti-CD20 antibody with great expectations.

Illidge TM.

Expert Opin Biol Ther. 2012 May;12(5):543-5. doi: 10.1517/14712598.2012.668881. Epub 2012 Mar 20. No abstract available.

PMID:
22428785
30.

Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway.

Honeychurch J, Alduaij W, Azizyan M, Cheadle EJ, Pelicano H, Ivanov A, Huang P, Cragg MS, Illidge TM.

Blood. 2012 Apr 12;119(15):3523-33. doi: 10.1182/blood-2011-12-395541. Epub 2012 Feb 21.

31.

Tumor cell embryonality and the ploidy number 32n: is it a developmental checkpoint?

Erenpreisa J, Cragg MS, Anisimov AP, Illidge TM.

Cell Cycle. 2011 Jun 1;10(11):1873-4. Epub 2011 Jun 1. No abstract available.

PMID:
21519193
32.

New antibody drug treatments for lymphoma.

Mayes S, Brown N, Illidge TM.

Expert Opin Biol Ther. 2011 May;11(5):623-40. doi: 10.1517/14712598.2011.560569. Epub 2011 Mar 14. Review.

PMID:
21395497
33.

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.

Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, Shimada K, Chan CH, Tutt A, Beers SA, Glennie MJ, Cragg MS, Illidge TM.

Blood. 2011 Apr 28;117(17):4519-29. doi: 10.1182/blood-2010-07-296913. Epub 2011 Mar 4.

34.

Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma.

Greystoke A, O'Connor JP, Linton K, Taylor MB, Cummings J, Ward T, Maders F, Hughes A, Ranson M, Illidge TM, Radford J, Dive C.

Br J Cancer. 2011 Feb 15;104(4):719-25. doi: 10.1038/sj.bjc.6606082. Epub 2011 Jan 18.

35.

The future of anti-CD20 monoclonal antibodies: are we making progress?

Alduaij W, Illidge TM.

Blood. 2011 Mar 17;117(11):2993-3001. doi: 10.1182/blood-2010-07-298356. Epub 2011 Jan 5.

36.

Validation of an ELISA for the determination of rituximab pharmacokinetics in clinical trials subjects.

Hampson G, Ward TH, Cummings J, Bayne M, Tutt AL, Cragg MS, Dive C, Illidge TM.

J Immunol Methods. 2010 Aug 31;360(1-2):30-8. doi: 10.1016/j.jim.2010.05.009. Epub 2010 Jun 11.

PMID:
20547164
37.

Radioimmunotherapy of lymphoma: a treatment approach ahead of its time or past its sell-by date?

Illidge TM.

J Clin Oncol. 2010 Jun 20;28(18):2944-6. doi: 10.1200/JCO.2009.26.8748. Epub 2010 May 10. No abstract available.

PMID:
20458052
38.

Radiotherapy research priorities for the UK.

Maughan TS, Illidge TM, Hoskin P, McKenna WG, Brunner TB, Stratford IJ, Harrington KJ, Plummer R, Billingham LJ, Nutting C, Burnet NG, Mackay RI, Oliver A, Young C, Chan CS; NCRI Clinical and Translational Radiotherapy Research Working Group.

Clin Oncol (R Coll Radiol). 2010 Oct;22(8):707-9. doi: 10.1016/j.clon.2010.03.006. Epub 2010 Apr 2. No abstract available.

PMID:
20363111
39.

Radioimmunotherapy: strategies for the future in indolent and aggressive lymphoma.

Alduaij W, Illidge TM.

Curr Oncol Rep. 2009 Sep;11(5):363-70. Review.

PMID:
19679011
40.

Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells.

Ivanov A, Beers SA, Walshe CA, Honeychurch J, Alduaij W, Cox KL, Potter KN, Murray S, Chan CH, Klymenko T, Erenpreisa J, Glennie MJ, Illidge TM, Cragg MS.

J Clin Invest. 2009 Aug;119(8):2143-59. doi: 10.1172/JCI37884. Epub 2009 Jul 20.

41.

Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy.

Illidge TM, Bayne M, Brown NS, Chilton S, Cragg MS, Glennie MJ, Du Y, Lewington V, Smart J, Thom J, Zivanovic M, Johnson PW.

Blood. 2009 Feb 12;113(7):1412-21. doi: 10.1182/blood-2008-08-175653. Epub 2008 Dec 12.

42.

Endopolyploidy in irradiated p53-deficient tumour cell lines: persistence of cell division activity in giant cells expressing Aurora-B kinase.

Erenpreisa J, Ivanov A, Wheatley SP, Kosmacek EA, Ianzini F, Anisimov AP, Mackey M, Davis PJ, Plakhins G, Illidge TM.

Cell Biol Int. 2008 Sep;32(9):1044-56. doi: 10.1016/j.cellbi.2008.06.003. Epub 2008 Jun 17.

44.

Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma.

Kim YH, Duvic M, Obitz E, Gniadecki R, Iversen L, Osterborg A, Whittaker S, Illidge TM, Schwarz T, Kaufmann R, Cooper K, Knudsen KM, Lisby S, Baadsgaard O, Knox SJ.

Blood. 2007 Jun 1;109(11):4655-62. Epub 2007 Feb 20.

45.

Upregulation of meiosis-specific genes in lymphoma cell lines following genotoxic insult and induction of mitotic catastrophe.

Kalejs M, Ivanov A, Plakhins G, Cragg MS, Emzinsh D, Illidge TM, Erenpreisa J.

BMC Cancer. 2006 Jan 9;6:6.

46.

Segregation of genomes in polyploid tumour cells following mitotic catastrophe.

Erenpreisa J, Kalejs M, Ianzini F, Kosmacek EA, Mackey MA, Emzinsh D, Cragg MS, Ivanov A, Illidge TM.

Cell Biol Int. 2005 Dec;29(12):1005-11. Epub 2005 Nov 28.

PMID:
16314119
47.
48.

What's new in the management of cutaneous T-cell lymphoma?

McFarlane V, Friedmann PS, Illidge TM.

Clin Oncol (R Coll Radiol). 2005 May;17(3):174-84. Review.

PMID:
15901002
49.

A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells.

Cragg MS, Bayne MB, Tutt AL, French RR, Beers S, Glennie MJ, Illidge TM.

Blood. 2004 Oct 15;104(8):2540-2. Epub 2004 Jun 22.

50.

Apparent modulation of CD20 by rituximab: an alternative explanation.

Cragg MS, Bayne MC, Illidge TM, Valerius T, Johnson PW, Glennie MJ.

Blood. 2004 May 15;103(10):3989-90; author reply 3990-1. No abstract available.

Supplemental Content

Loading ...
Support Center